These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 36461653)

  • 1. Saxagliptin: A potential doping agent? A randomized, double-blinded, placebo-controlled, and crossover pilot study in young active men.
    Bourdillon N; Eugster PJ; Vocat C; Nguyen T; Wuerzner G; Grouzmann E; Millet GP
    Physiol Rep; 2022 Dec; 10(23):e15515. PubMed ID: 36461653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetics of neuropeptide Y, catecholamines, and physiological responses during moderate and heavy intensity exercises.
    Eugster PJ; Bourdillon N; Vocat C; Wuerzner G; Nguyen T; Millet GP; Grouzmann E
    Neuropeptides; 2022 Apr; 92():102232. PubMed ID: 35180646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NPY1-36 and PYY1-36 activate cardiac fibroblasts: an effect enhanced by genetic hypertension and inhibition of dipeptidyl peptidase 4.
    Zhu X; Gillespie DG; Jackson EK
    Am J Physiol Heart Circ Physiol; 2015 Nov; 309(9):H1528-42. PubMed ID: 26371160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proneuropeptide Y and neuropeptide Y metabolites in healthy volunteers and patients with a pheochromocytoma or paraganglioma.
    Eugster PJ; Maurer J; Vocat C; Abid K; Matter M; Wuerzner G; Trepp R; Fischli S; Henzen C; Kolb W; Bilz S; Sigrist S; Beuschlein F; Nölting S; Reul A; Schütze I; Hubers SA; Brown NJ; Grouzmann E
    Clin Chim Acta; 2022 Sep; 534():146-155. PubMed ID: 35905838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiplexed Assay to Quantify the PP-Fold Family of Peptides in Human Plasma Using Microflow Liquid Chromatography-Tandem Mass Spectrometry.
    Reverter-Branchat G; Eugster PJ; Kuenzli C; Rindlisbacher B; Stauffer T; Nakas CT; Herzig D; Grouzmann E; Bally L
    Clin Chem; 2022 Mar; 68(4):584-594. PubMed ID: 35015868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Saxagliptin Cardiotoxicity in Chronic Heart Failure: The Role of DPP4 in the Regulation of Neuropeptide Tone.
    Vörös I; Onódi Z; Tóth VÉ; Gergely TG; Sághy É; Görbe A; Kemény Á; Leszek P; Helyes Z; Ferdinandy P; Varga ZV
    Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35884882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.
    Wang A; Dorso C; Kopcho L; Locke G; Langish R; Harstad E; Shipkova P; Marcinkeviciene J; Hamann L; Kirby MS
    BMC Pharmacol; 2012 Apr; 12():2. PubMed ID: 22475049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DPP4 Inhibition, NPY
    Jackson EK; Gillespie DG; Tofovic SP
    J Pharmacol Exp Ther; 2020 Apr; 373(1):135-148. PubMed ID: 32015161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease.
    Chen L; Zhang X; Zhang L; Zheng D
    Diabetes Metab Syndr Obes; 2020; 13():3507-3518. PubMed ID: 33116702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of acute vs chronic treatment with beta-adrenoceptor blockade on exercise performance, haemodynamic and metabolic parameters in healthy men and women.
    Gullestad L; Hallen J; Medbø JI; Grønnerød O; Holme I; Sejersted OM
    Br J Clin Pharmacol; 1996 Jan; 41(1):57-67. PubMed ID: 8824694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipeptidyl peptidase IV (DPP4)-deficiency attenuates diet-induced obesity in rats: possible implications for the hypothalamic neuropeptidergic system.
    Stephan M; Radicke A; Leutloff S; Schmiedl A; Pabst R; von Hörsten S; Dettmer S; Lotz J; Nave H
    Behav Brain Res; 2011 Jan; 216(2):712-8. PubMed ID: 20887754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved ventilation and decreased sympathetic stress in chronic heart failure patients following local endurance training with leg muscles.
    Gordon A; Tyni-Lenné R; Jansson E; Kaijser L; Theodorsson-Norheim E; Sylvén C
    J Card Fail; 1997 Mar; 3(1):3-12. PubMed ID: 9110249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catecholamines response of high performance wheelchair athletes at rest and during exercise with autonomic dysreflexia.
    Schmid A; Schmidt-Trucksäss A; Huonker M; König D; Eisenbarth I; Sauerwein H; Brunner C; Storch MJ; Lehmann M; Keul J
    Int J Sports Med; 2001 Jan; 22(1):2-7. PubMed ID: 11258636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute and long-term effects of saxagliptin on a set of cardiovascular targets measured at fasting and post-prandially in obese patients with impaired glucose tolerance: A placebo-controlled study.
    Rezki A; Cosson E; Fysekidis M; Chiheb S; Vicaut E; Valensi P
    Nutr Metab Cardiovasc Dis; 2021 Sep; 31(10):2945-2958. PubMed ID: 34420816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased Dipeptidyl Peptidase-4 Activity Is Associated With High Prevalence of Depression in Middle-Aged and Older Adults: A Cross-Sectional Study.
    Zheng T; Liu Y; Qin S; Liu H; Yang L; Zhang X; Li G; Li Q
    J Clin Psychiatry; 2016 Oct; 77(10):e1248-e1255. PubMed ID: 27529287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials.
    Ling J; Cheng P; Ge L; Zhang DH; Shi AC; Tian JH; Chen YJ; Li XX; Zhang JY; Yang KH
    Acta Diabetol; 2019 Mar; 56(3):249-272. PubMed ID: 30242726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes.
    Rosenstock J; Sankoh S; List JF
    Diabetes Obes Metab; 2008 May; 10(5):376-86. PubMed ID: 18355324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute Effects of Breakfast Fruits Meal Sequence and Postprandial Exercise on the Blood Glucose Level and DPP4 Activity among Type 2 Diabetes Mellitus Patients: A Pilot Study.
    Dono I; Dwipajati D; Dirgahayu P; Wibowo YC; Pratama YM
    J Obes; 2022; 2022():4875993. PubMed ID: 36204396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of DPP4 inhibitors on the levels of plasma catecholamines and their metabolites in patients with type 2 diabetes.
    Kim TH; Lee K; Park IB; Choi CS; Ahn TH; Lee DH
    Diabetes Res Clin Pract; 2019 Oct; 156():107832. PubMed ID: 31513823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying neuropeptide Y (NPY) as the main stress-related substrate of dipeptidyl peptidase 4 (DPP4) in blood circulation.
    Wagner L; Kaestner F; Wolf R; Stiller H; Heiser U; Manhart S; Hoffmann T; Rahfeld JU; Demuth HU; Rothermundt M; von Hörsten S
    Neuropeptides; 2016 Jun; 57():21-34. PubMed ID: 26988064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.